Plus Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Plus Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Plus Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Plus Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Plus Therapeutics Inc (Plus Therapeutics) is a developmental-stage pharmaceutical company, which focuses on the discovery, development and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s lead radiotherapeutic candidate, rhenium obisbemeda, is targeted at CNS cancers such as recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC). It is also developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), for treating various solid organ cancers, including primary and secondary liver cancers, via intra-arterial injection. The company uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Houston, Texas, the US.
Headquarters
United States of America
Address
Suite 210, 6420 Levit Green Boulevard, Houston, Texas, 77021
Website
www.plustherapeutics.com
Telephone
1 210 9746900
No of Employees
28
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PSTV (NASD)
Revenue (2024)
$5.2M
-10.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-72.5%
(2024 vs 2023)
Market Cap*
$28.6M
Net Profit Margin (2024)
XYZ
-92.7%
(2024 vs 2023)
* As of and is in US$
Plus Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | REYOBIQ |
| RESPECT-LM Trial -Single Dose: Leptomeningeal Metastases | CNSide |
| RESPECT-LM Trial -Multi Dose: Leptomeningeal Metastases | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company's subsidiary CNSide Diagnostics entered into an agreement with UnitedHealthcare Insurance Company for CNSide cerebrospinal fluid assay for metastatic CNS cancer. |
| 2025 | Contracts/Agreements | In June, the company entered into an agreement with the FDA to initiate ReSPECT-LM dose optimization trial for REYOBIQ in leptomeningeal metastases. |
| 2025 | Regulatory Approval | In June, the company announced FDA clearance of its investigational new drug application using Reyobiq for the treatment of childhood brain cancer. |
Competitor Comparison
| Key Parameters | Plus Therapeutics Inc | Bayer AG | VBI Vaccines Inc | PharmAbcine Inc | MediciNova Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | United States of America | South Korea | United States of America |
| City | Houston | Leverkusen | Cambridge | Daejeon | La Jolla |
| State/Province | Texas | Nordrhein-Westfalen | Massachusetts | Seoul | California |
| No. of Employees | 28 | 87,757 | 131 | 24 | 6 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard J. Hawkins | Chairman | Executive Board | 2018 | 76 |
| Marc H. Hedrick, M.D. | Chief Executive Officer; President; Director | Executive Board | 2014 | 63 |
| Andrew Sims | Chief Financial Officer; Vice President | Senior Management | 2020 | 52 |
| Eric J. Daniels, M.D. | Chief Development Officer | Senior Management | 2026 | - |
| Russell Bradley | General Manager - CNSide Diagnostics; President - CNSide Diagnostics | Executive Board | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer